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We analyze the epidemiological characteristics and outcomes of 72 patients diagnosed with non-metastatic
inflammatory breast cancer (IBC) at National Institute of Oncology of Rabat in Morocco, between January 2007 and
December 2008. IBC patients represent 5% of all breast cancers (90/1800). The median age of patients was 47 years.
Thirty eight patients (53%) had premenoposal status and 69% of the cases had clinical lymph nodes. The dominant
pathological funding was infiltrating ductal carcinoma (96%). Most patients had high grade II/III (77.8%), 43.4% of
the cases were ER negative and 47.4% of the tumors overexpress the HER2/neu receptor on IHC. Only 48.6% of the
patients received completed treatment (chemotherapy [CT], surgery and radiotherapy [RT]) and all patients received
anthracycline based neoadjuvant CT, 51.4% of whom received Taxane. Seventy one% of the patients underwent
surgery and 54% received RT. The clinical response to CT was 68%. Only 1 (1.4%) patient has pathological complete
response (pCR) in the breast and 5 (7%) had pathologically negative lymph-nodes. Patient who achieved pCR was
disease free at 27 months. LRRFS, EFS and OS rates at 1–2 years were 90.8%-78.1%, 81.7%-57.5%, and 94.3%-74.6%,
respectively. Patients with ER-negative status (EFS: P = 0.043) had poorer outcomes and RT was associated with
highly significant increase in LRRFS, EFS and OS (P < 0.0001, P < 0.001 and P = 0.017).To the editor
Inflammatory breast cancer (IBC) is a rare and aggres-
sive clinical form of BC representing less than 2% of all
BC in westerns countries. However, in North Africa, the
incidence of IBC is higher accounting for more than 5%
of all BC. It is diagnosed clinically by the rapid onset of
diffuse erythema and edema (peau d’orange) of at least a
third of the skin overlying the breast that rapidly extends
to the entire breast. IBC appears to behave as an
ER-negative subtype and HER2-positive subtype. In
addition, studies of molecular biology identified several
anomalies such as EGFR1 over-expression. Considering
cell-of-origin subtypes, most cases of IBC belong to* Correspondence: ismailinabil@yahoo.fr
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stated.the basal, the luminal-B, or the HER2-overexpressing
subtype. The treatment of this disease has evolved sig-
nificantly during the past three decades, incorporating
combined modality; chemotherapy, surgery and radio-
therapy. The 5- and 10-year overall survival rate was
56% and 35%, respectively for patients who have re-
ceived multimodal therapy [1-4].
From 1800 patients having the diagnosis of BC
registered at the National Institute of Oncology of
Rabat between January 2007 and December 2008, we
identified 90 patients (5% of BC) diagnosed (accord-
ing to the international criteria) with IBC. Table 1
analyzes patient characteristics and outcomes. In our
study, we included 72 patients with nonmetastatic
IBC. The median age of patients was 47 years and
the dominant histology was infiltrating ductal carcin-
oma (96%). Most patients had high nuclear grade II/
III (77.8%), 43.4% [23/53] were ER-negative andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Table 1 Patient characteristics and outcomes
Characteristics All patients
(n = 90)
5% of all breast








Range 29 - 75 29 - 75
Menoposal status
Premenoposal 51 (56.7%) 38 (53%)
Postmenoposal 34 (37.8%) 30
Unknown 5 4
Histilogy
Infiltrating ductal carcinoma 84 (93.3%) 69 (96%)
Infiltrating lobular carcinoma 3 (3.3%) 2
Other 3 (3.3%) 3
SBR
I 5 (5.6%) 4
II 45 (50%) 36
III 24 (26.7%) 20




ER-/PR+ 23 19 (26.4%)
ER-/PR- 4 4 (5.6%)
Unknown 26 19
HER2/neu status




N0 31 (34.4%) 23 (32%)
N1 42 (46.7%) 33
N2 12 (13.3%) 12
N3 5 (5.6%) 4
Clinical stage M
M0 72 (80%) 72
M1 18 (20%) 0
Taxanes
Yes 45 37 (51.4%)
No 43 35 (48.6%)
Unknown 2 0
Surgery
Yes 53 51 (71%)
No 37 21 (29%)
Table 1 Patient characteristics and outcomes (Continued)
Radiotherapy
Yes 40 39 (54%)
No 50 33 (36%)
cOR (CR + PR) - 49 (68%)




1 and 2 y LRRFS - 90.8%; 78.1%
1 and 2 y EFS - 81.7%; 57.5%
1 and 2 y OS - 94.3%; 74.6%
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48.6% of the patients received completed treatment
(CT, surgery, and RT). All patients received anthra-
cycline neoadjuvant CT, 37 (51.4%) received Taxane
and one received Trastuzumab. Fifty one patients
(71% of the cases) underwent surgery (mastectomy)
and 54% received RT.
Outcomes of our patients are poor in concordance
with a recent American study [5]; cOR was 68% and
only 1 (1.4%) patient had pCR in the breast and 5
(7%) in lymph nodes. At 15 months median follow-
up, LRRFS, EFS and OS rates at 1–2 years were
90.8%-78.1%, 81.7%-57.5%, and 94.3%-74.6%, respect-
ively (Figures 1A, B, and C, respectively). Patients
with ER-negative tumors had worse prognosis than
patients with ER + tumors; the difference in EFS be-
tween the two groups was statistically significant (P
= 0.043) (Figure 1D). RT was associated with signifi-
cant increase of LRRFS, EFS and OS (P < 0.0001, P <
0.001 and P = 0.017, respectively) (Figures 1E, F and
G). These data confirmed the higher impact of RT
in the management of this aggressive disease. In
addition, others factors have been demonstrated to
influence survival in patients with IBC according to
the most powered investigations, such as menopausal
status, nuclear grade, lymphovascular invasion, surgi-
cal margins and Trastuzumab [6-11]. We analyzed
the impact of these factors on the outcomes of IBC
patients; however, due to the limited statistical
power of the cohort, no other significant factors
were identified. Only 35 patients had the determin-
ation of the HR status and the HER2 status. Kaplan
Meier curves showed that ER+/HER2- and ER
+/HER2+ patients had better outcome than ER-/
HER2+ and ER-/HER2- patients, however the differ-
ence was not significant (P = 0.3) (Figure 1H).
Figure 1 The figure below shows the outcomes of nonmetastatic IBC in Morocco (A, B and C), the prognostic factors (D, E, F and G)
and the impact of molecular subtypes (H). A: LRRFS probability in nonmetastatic IBC patients; B: EFS probability in nonmetastatic IBC patients;
C: OS probability in nonmetastatic IBC patients; D: Positive effect of ER-positive status in EFS; E: Positive impact of RT in LRRFS; F: Positive impact
of RT in EFS; G: Positive impact of RT in OS; H: Survival according to molecular subtypes.
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